Found 12 grace-kim-lee trials
A listing of grace-kim-lee medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
For subjects age 18 years and older who are at an increased risk for HCC and for whom HCC surveillance is appropriate, including subjects with cirrhosis or non-cirrhotic subjects with Hepatitis B. Approximately 3,000 subjects are expected to be enrolled, comprised of approximately 2,222 ultrasound surveillance subjects and 778 subjects …
A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects with Severe Alcohol-Associated Hepatitis.
The purpose of this study is to test the effectiveness (how well the study drug works) and safety of BMS-986263 in participants with compensated cirrhosis from nonalcoholic steatohepatitis (NASH). The study drug BMS-986263, is investigational. An investigational drug is one that is not approved by the United States Food and …
The purpose of this study is to determine the safety and tolerability of an experimental medication PLN-74809 to treat primary Sclerosing Cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver. Participants will visit the study center 8 times within 22 weeks. …
To evaluate the safety and tolerability of zetomipzomib in patients with autoimmune hepatitis (AIH) and to evaluate the efficacy of the drug in addition to standard-of-care in patients with AIH who have failed standard-of-care treatment. Target population = 3 subjects. Subjects will be randomized to either treatment or control and …
The goal of study 1 and study 2 is to evaluate the effects of ALN-HSD on liver fibrosis and other histologic features of NASH in participants with NASH and F2/F3 fibrosis and risk alleles for HSD17B13. Necessary screening procedures include blood tests, liver stiffness measurement, study-specific genotype criteria, and a …
1 - 10 of 12
- 1
- 2
